Home › Blog › One Drug, Two Jobs: Treating the Lungs and "Reversing Age" — The Proteomic Age Clock Enters the Clinical Trial
Back to Blog

One Drug, Two Jobs: Treating the Lungs and "Reversing Age" — The Proteomic Age Clock Enters the Clinical Trial

Six independent "biological age" dashboards light up green together for the first time in the same trial

In 2026, a clinical trial published in Nature Biotechnology did something no one had done before: within a single trial, it used six different "proteomic age clocks" at the same time to test whether a new drug could make participants' bodies "younger." This article explains, in plain language, what the study actually did, why it matters, and what its limits are.

Background: We Are at War with "Getting Old"

The human body ages, and many diseases — such as pulmonary fibrosis (scar tissue builds up in the lungs, making it harder to breathe) — are essentially "of the same root" as aging. Scientists have long wanted a single drug that both treats the disease and makes the whole body a little younger.

The old problem: how do you prove a drug really makes the body "younger"? Looking only at whether lung function improves is not enough. You need an "age clock."

What Is an "Age Clock"

Imagine your body has an internal "dashboard" with hundreds of "pointers" (in reality, proteins in the blood). Each pointer reflects some aspect of the body's state. Taken together, they compute a "biological age" — which may be higher or lower than your ID-card age.

Scientists have traditionally built these clocks from DNA methylation (chemical marks on DNA). Recently, proteins as the clock have become a new direction, because proteins are the molecules that actually "do the work" in the body — DNA methylation is more like "the buttons on the remote," while proteins are "the picture on the TV," showing you what is actually happening.

What This Paper Did

The Longevity Technologies team (led by Alex Zhavoronkov, a well-known scientist in the anti-aging field) did something no one had done before:

In a single clinical trial, use six different "proteomic age clocks" at the same time to see whether a new drug can make participants "younger."

The drug is called Rentosertib, an AI-designed novel compound (created by Insilico Medicine's AI platform) that specifically inhibits a protein called TNIK — think of it as an "aging switch" in the body. It is being tested for idiopathic pulmonary fibrosis (IPF), a lung disease in which lung tissue is progressively replaced by scar and for which there is currently no good treatment.

How the Trial Was Run

The Core Finding: Six Referees, Same Verdict

All six different proteomic age clocks consistently showed: patients on the real drug saw their biological age drop; patients on placebo showed no change.

This convergence — "six independent referees giving the same verdict" — greatly strengthens the credibility.

"Twice a day" Beats "Double Dose Once"

This is the most counterintuitive finding:

Why? The researchers' explanation: the drug does not stay in the body long (half of it is cleared within 7–11 hours). A single 60 mg dose makes blood levels spike then crash, like a roller coaster; 30 mg morning and evening keeps levels steadier, like cruising at constant speed. Steady drug levels may better influence the molecular switches tied to "aging," while the spike-and-crash levels mainly affect the "fibrosis" pathways.

A metaphor: if you want fewer weeds to grow in your garden (anti-aging), spreading the herbicide evenly beats dumping it all at once; but if you want to urgently clear vines that have already grown (anti-fibrosis), a heavy dump may be more direct.

"Getting Younger" and "Lungs Getting Better" Are Two Different Things

This is the paper's most important insight. The researchers found:

This means Rentosertib's anti-aging effect is not simply "the lungs got better, so the person looks younger" — it may genuinely be independently influencing the body's aging process.

The Body's "Aging Junk" Really Is Decreasing

The researchers specifically examined protein markers tied to "cellular senescence" (cells that stop working but don't die, continually releasing inflammatory signals):

At the same time, proteins associated with insulin-like growth factor (IGF) — a known aging driver pathway targeted by anti-aging interventions such as "caloric restriction" and "rapamycin" — were significantly down-regulated.

A Summing-Up Metaphor

Think of the body as a house:

This paper = the first time six different "house inspectors" simultaneously confirm: yes, this house is genuinely getting newer — and "getting newer" and "wiping the mold" are two separate things.

What Are the Limits

Why This Paper Matters

  1. For the first time, multiple proteomic "age clocks" were systematically compared in a clinical trial, showing they can consistently detect a drug's anti-aging signal.
  2. It proposes a practical strategy: measure the anti-aging effect incidentally within a disease trial, rather than running a standalone "anti-aging" trial (the latter is very hard to get through regulators).
  3. It found that dosing frequency may influence the anti-aging effect — a lesson for the design of all future anti-aging drugs.
  4. It provides a reference for the regulatory path of "anti-aging drugs": start as an exploratory endpoint inside a disease trial, then advance step by step.

Original published in Nature Biotechnology, 2026. The team is from Longevity Technologies and other institutions; corresponding author Alex Zhavoronkov is a prominent scientist in the anti-aging field. The drug Rentosertib was designed by Insilico Medicine's AI platform and targets the TNIK kinase — a landmark candidate at the intersection of "AI drug discovery + anti-aging." September 9, 2026